Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer

J Thorac Cardiovasc Surg. 1981 Apr;81(4):485-92.

Abstract

One hundred sixty-nine patients were entered into randomized controlled studies of intrapleural bacille Calmette Guérin (BCG) immunotherapy after surgical resection of lung cancer. Long-term follow-up of our initial series of BCG-treated patients with Stage I disease continues to indicate that this treatment was superior to that given to control patients. The recurrence rate in the control population was high, 62% at 3 years. The recurrence rate was 33% at 3 years in the BCG-treated group. A negative preoperative tuberculin test and squamous cell histologic type were favorable prognostic factors for BCG-treated patients. The survival of patients with more advanced disease was not improved by BCG immunotherapy.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • BCG Vaccine / administration & dosage
  • BCG Vaccine / therapeutic use*
  • Carcinoma, Squamous Cell / surgery*
  • Carcinoma, Squamous Cell / therapy
  • Clinical Trials as Topic
  • Female
  • Follow-Up Studies
  • Humans
  • Immunotherapy
  • Isoniazid / therapeutic use
  • Lung Neoplasms / surgery*
  • Lung Neoplasms / therapy
  • Middle Aged
  • Pleura
  • Random Allocation
  • Time Factors

Substances

  • BCG Vaccine
  • Isoniazid